Association of race with cumulative exposure to statins in dialysis

American Journal of Nephrology

Volumn 36, Issue 1, 2012, Pages 90-96

  Wetmore, James B ^a   Mahnken, Jonathan D ^b   Rigler, Sally K ^b   Ellerbeck, Edward F ^b   Mukhopadhyay, Purna ^b   Hou, Qingjiang ^b   Shireman, Theresa I ^a,b  

^a Kidney Institute   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Dialysis; End stage renal disease; HMG CoA reductase inhibitors; Medicaid; Medicare; Medication exposure; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AFRICAN AMERICAN; ARTICLE; CARDIOVASCULAR DISEASE; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DIALYSIS; DRUG EXPOSURE; ETHNICITY; FEMALE; HEALTH CARE PERSONNEL; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RACE;

ADOLESCENT; ADULT; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; ETHNIC GROUPS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEAST-SQUARES ANALYSIS; MALE; MEDICAID; MEDICARE; MIDDLE AGED; ODDS RATIO; REGRESSION ANALYSIS; RENAL DIALYSIS; SOCIAL CLASS; UNITED STATES;

EID: 84862726467     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000339626     Document Type: Article

References (23)

1. Trivedi AN, Zaslavsky AM, Schneider EC, Ayanian JZ: Relationship between quality of care and racial disparities in Medicare health plans. JAMA 2006; 296: 1998-2004. (Pubitemid 44631446)
2. Joynt KE, Orav EJ, Jha AK: Thirty-day read-mission rates for Medicare beneficiaries by race and site of care. JAMA 2011; 305: 675-681.
3. Wasse H, Speckman RA, Frankenfield DL, Rocco MV, McClellan WM: Predictors of de-layed transition from central venous catheter use to permanent vascular access among ESRD patients. Am J Kidney Dis 2007; 49: 276-283. (Pubitemid 46178403)
4. Hopson S, Frankenfield D, Rocco M, Mc-Clellan W: Variability in reasons for hemo-dialysis catheter use by race, sex, and geogra-phy: findings from the ESRD Clinical Per-formance Measures Project. Am J Kidney Dis 2008; 52: 753-760.
5. Cavanaugh KL, Wingard RL, Hakim RM, Elasy TA, Ikizler TA: Patient dialysis knowl-edge is associated with permanent arteriove-nous access use in chronic hemodialysis. Clin J Am Soc Nephrol 2009; 4: 950-956.
6. Chakkera HA, O'Hare AM, Johansen KL, Hynes D, Stroupe K, Colin PM, Chertow GM: Influence of race on kidney transplant outcomes within and outside the Depart-ment of Veterans Affairs. J Am Soc Nephrol 2005; 16: 269-277. (Pubitemid 43073182)
7. Hall YN, Choi AI, Xu P, O'Hare AM, Cher-tow GM: Racial ethnic differences in rates and determinants of deceased donor kidney transplantation. J Am Soc Nephrol 2011; 22: 743-751.
8. Powe NR: Let's get serious about racial and ethnic disparities. J Am Soc Nephrol 2008; 19: 1271-1275.
9. Poon I, Lal LS, Ford ME, Braun UK: Racial/ ethnic disparities in medication use among veterans with hypertension and dementia: a national cohort study. Ann Pharmacother 2009; 43: 185-193.
10. Mehta JL, Bursac Z, Mehta P, Bansal D, Fink L, Marsh J, Sukhija R, Sachdeva R: Racial dis-parities in prescriptions for cardioprotective drugs and cardiac outcomes in Veterans Af-fairs Hospitals. Am J Cardiol 2010; 105:1019-1023.
11. Litaker D, Koroukian S, Frolkis JP, Aron DC Disparities among the disadvantaged: varia-tion in lipid management in the Ohio Med-icaid program. Prev Med 2006; 42:313-315.
12. Wetmore JB, Mahnken JD, Mukhopadhyay P, Hou Q, Ellerbeck EF, Rigler SK, Spertus JA, Shireman TI: Geographic variation in cardioprotective antihypertensive medica-tion usage in dialysis patients. Am J Kidney Dis 2011; 58: 73-83.
13. Wetmore JB, Rigler SK, Mahnken JD, Mu-khopadhyay P, Shireman TI: Considering health insurance: how do dialysis initiates with Medicaid coverage differ from persons without Medicaid coverage? Nephrol Dial Transplant 2010; 25: 198-205.
14. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in pa-tients with type 2 diabetes mellitus undergo-ing hemodialysis. N Engl J Med 2005; 353: 238-248. (Pubitemid 41058323)
15. Fellstrom BC, Jardine AG, Schmieder RE, et al: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407.
16. Baigent C, Landray MJ, Reith C, et al: The effects of lowering LDL cholesterol with sim-vastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192.
17. Liu J, Huang Z, Gilbertson DT, Foley RN, Collins AJ: An improved comorbidity index for outcome analyses among dialysis pa-tients. Kidney Int 2010; 77:141-151.
18. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J: Long-term per-sistence in use of statin therapy in elderly pa-tients. JAMA 2002; 288:455-461. (Pubitemid 34787476)
19. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB: Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009; 15:728-740.
20. Curtin RB, Svarstad BL, Keller TH: Hemo-dialysis patients' noncompliance with oral medications. ANNA J 1999; 26: 307-316, dis-cussion 317, 335.
21. Charles H, Good CB, Hanusa BH, Chang CC, Whittle J: Racial differences in adher-ence to cardiac medications. J Natl Med As-soc 2003; 95:17-27 (Pubitemid 37101972)
22. Arnold SV, Chan PS, Jones PG, Decker C, Buchanan DM, Krumholz HM, Ho PM, Spertus JA: Translational Research Investi-gating Underlying Disparities in Acute Myo-cardial Infarction Patients' Health Status (TRIUMPH): design and rationale of a pro-spective multicenter registry. Circ Cardio-vasc Qual Outcomes 2011; 4:467-476.
23. Mason NA, Bailie GR, Satayathum S, Bragg-Gresham JL, Akiba T, Akizawa T, Combe C, Rayner HC, Saito A, Gillespie BW, Young EW: HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 2005; 45:119-126. (Pubitemid 40038052)